Clinical Scenario

This protocol addresses patients with symptomatic hemolytic PNH requiring active first-line intervention. Treatment strategy is guided by patient-specific factors and the availability of multiple complement inhibitor options.

Treatment Approach — Partial Overview

First-line management centers on complement inhibition. Multiple agents are available, including options given intravenously as well as those taken orally or subcutaneously. Meningococcal vaccination is mandatory at the initiation of any complement inhibitor therapy. The complete agent selection, accompanying measures, and full clinical algorithm are contained in the structured protocol.

Hematologic Response Goals

No transfusion requirement

Hemoglobin ≥ 12 g/dl

LDH ≤ 1.5× upper limit of normal

Reticulocytes ≤ 150/nl

Response assessed as the median value over 6 months (complete response definition).

References

An accompanying vaccination against meningococci is mandatory for treatment with complement inhibitors.
The approval of Iptacopan and the extension of the approval of Pegcetacoplan allow both substances to be used as first-line treatment for hemolytic PNH.
The assessment of the response under C5 complement inhibition can be evaluated on the basis of transfusion requirements, LDH, hemoglobin levels and the reticulocyte count (absolute value).
For assessment, the median value of hemoglobin, LDH and reticulocytes should be assessed over 6 months.

View source ↗

First-Line Treatment of Symptomatic Hemolytic Paroxysmal Nocturnal Hemoglobinuria